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Induction of DNA damage by chemotherapeutics hasbeen the mainstay of cancer therapy irrespective ofthe origin of the cancer. However, in acute myeloid
leukemia (AML) responses to intensive chemotherapy
differ greatly, with the success rate ranging very widely
from 94% to 17% depending upon the karyotype of the
patients.1 In particular, AML patients with normal cytoge-
netics initially respond to DNA damaging agents but fre-
quently relapse and have a 5-year survival rate of around
30%. The inferior survival in these patients correlates
with the presence of internal tandem duplications (ITD)
in FLT3, a cytokine receptor with tyrosine kinase activity,
found in almost one-third of AML patients.
Constitutively active FLT3-ITD contributes to increased
proliferation and survival of myeloid progenitor cells.
Although FLT3-ITD by itself is not considered a driver of
AML, the presence of the mutation at both diagnosis and
relapse highlights the importance of FLT3-ITD in resist-
ance of leukemia-initiating cells to therapy. FLT3-ITD can
activate all the major signaling pathways, such as
Ras/ERK, JAK/STAT5 and PI3K/AKT but we still do not
completely understand how these lead to resistance to
chemotherapy and whether they create any vulnerabili-
ties that could be exploited. FLT3-ITD activates the
NADPH oxidase system through RAC1 to augment the
production of reactive oxygen species (ROS) and a conse-
quent adaptive response involving RAD51-mediated
error prone repair and enhanced genomic instability.2
Interestingly, increased ROS production is not associated
with the tyrosine kinase domain mutated FLT3, which
incidentally is also not associated with poor prognosis.
These suggest that increased DNA damage response
(DDR) and genomic instability are important for the poor
response to therapy in FLT3-ITD-positive (FLT3-ITD+)
AML patients. In the current issue of Haematologica, Wu et
al.3 provide evidence of involvement of a FLT3-
ITD/DOCK2/ RAC1 self-sustaining positive feedback
loop leading to upregulation of DDR proteins that con-
tributes to chemotherapy resistance (Figure 1). They pro-
vide evidence for the crucial role played by DOCK2 in
mediating chemoresistance through regulating the
RAC1/STAT5/DDR axis.3 Although expression of FLT3-
ITD has been associated with resistance to chemothera-
py and it has long been known that inhibition of signaling
by kinase inhibitors can sensitize leukemic cells,4 this had
not been extensively explored or utilized in the clinic.
Only recently, is it becoming evident that midostaurin
(PKC412), a multi-kinase inhibitor, is much more effec-
tive at inducing sustained remissions when used in com-
bination with chemotherapy than when used as single-
agent therapy.5 The results presented by Wu et al.3 further
emphasize the role of chemo-sensitization through inhi-
bition of signaling by mutant FLT3 and provide a way for-
ward for improving the clinical outcome in FLT3-ITD+
AML patients. 
Activation of RAC1 by FLT3-ITD has been recognized
as the major contributor to enhanced DDR but the ubiq-
uitous expression of RAC1 and its involvement in multi-
ple processes makes targeting RAC1 specifically in
leukemic cells a challenge.6 DOCK2, an atypical guanine
nucleotide exchange factor, has previously been identi-
fied as an intermediate between FLT3-ITD and STAT5.7
DOCK2 has much more restricted expression, acts
upstream of RAC1 and is required for upregulation of the
DDR pathway. Combining loss of DOCK2 with cytara-
bine produced a similar increase in cytotoxicity as that
observed with inhibiting the kinase function of FLT3-ITD
(Figure 1).3 The alternative pathways from FLT3-ITD,
such as FAK/TIAM1 and DOCK2, culminating in activa-
tion of RAC1 and subsequent nuclear translocation of
STAT5 provide additional points of vulnerability that
could be therapeutically exploited to overcome acquired
drug resistance in response to FLT3-specific small mole-
cule inhibitors.7,8 DOCK2 mutations leading to activation
of RAC1 have also been identified in gastrointestinal and
prostate cancers. It remains to be seen if similar deregula-
tion of the DDR pathway is involved in carcinogenesis
across different types of cancers.
The synthetic lethality observed with DOCK2 inhibi-
tion upon treatment with cytarabine could be attributed
to downregulation of FLT3-ITD and the DDR pathway.3
However, Wu et al.3 did not observe a similar synergism
when inhibitors of individual components of the DDR
such as CHK1 (MK8776) or WEE1 (MK1775) were used
in combination with cytarabine. As expected, the concur-
rent use of inhibitors of CHK1 and WEE1 with DOCK2
inhibition showed marginal improvements since DOCK2
knockdown significantly reduces both FLT3-ITD and
these DDR pathway proteins.3 Functional redundancy
between DDR proteins may account for lack of syner-
gism between MK8776 or MK1775 and cytarabine.3
Although targeting DOCK2 appears to be more benefi-
cial; the clinical translation of co-targeting DOCK2 is lim-
ited due to non-availability of potent and specific
inhibitors. Currently two small molecule inhibitors of
DOCK2 are available: the chemically synthesized 4-[3’-
(2’’-chlorophenyl)-2’-propen-1’-ylidene]-1-phenyl-3,5-
pyrazolidinedione (CPYPP)9 and a naturally occurring
cholesterol sulfate.10 The effects of these inhibitors of
DOCK2 have been evaluated in the immune system and
they have been found to block RAC1 activation but a
comprehensive evaluation in AML models has not been
carried out. The significance of targeting DOCK2 in sen-
sitizing FLT3-ITD+ AML cells to chemotherapy demon-
strated by Wu et al.3 may provide the impetus for devel-
opment of therapeutic strategies to target DOCK2 in
combination with standard chemotherapy leading to bet-
ter prognosis for these AML patients.   
While the study by Wu et al.3 focuses only on FLT3-
ITD+ AML, similar defects in the DDR are known to be
associated with several other AML driver mutations,
specifically the epigenetic regulators. Genes such as
DNMT3A and TET2, which are very frequently mutated
not only in the leukemic cells but also in the pre-
leukemic clones, are known to regulate the DDR.11,12
Cells carrying mutations in these genes are known to
have an increased propensity to accumulate DNA dam-
age. Interestingly, they are also found in non-random
association with FLT3-ITD and their concurrent occur-
rence is sufficient for AML initiation. Similar to FLT3-
ITD these pre-leukemic mutant clones tend to be chemo-
resistant and they expand following elimination of
leukemic cells by chemotherapy. The pre-leukemic
clones are believed to evolve into leukemic cells due to
inherent genomic instability and acquisition of addition-
al mutations. The clinical relevance of alterations in the
DDR in AML due to genetic mutations is underscored by
the increase in survival with induction therapy dose
escalation observed in patients carrying mutant
DNMT3A but not in their wildtype counterparts.13 With
better understanding of the driver mutations in AML and
their role in normal cell functions, it is becoming appar-
ent that an altered DDR is a common underlying theme
in AML and pre-leukemic mutant cells. The research by
Wu et al.3 emphasizes that combinatorial treatment
strategies tailored to the specific driver mutation-depen-
dent vulnerability in the DDR need to be explored fur-
ther. A similar approach of inducing synthetic lethality
by using PARP inhibitors in combination with standard
chemotherapy in BRCA mutated gynecological cancers
has led to improved patients’ outcomes in the clinic.14
Interestingly, FLT3-ITD+ leukemic cells can be sensitized
to PARP inhibitors when used in combination with
AC220, a second-generation FLT3 inhibitor, leading to
enhanced survival.15 It is to be hoped that these studies
will spur development of rational combinations of
inhibitors of FLT3 signaling with DDR inhibitors leading
to a broader range of options to improve patients’ out-
comes and survival. 
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Figure 1. FLT3-ITD and DOCK2 maintain the bal-
ance between the DNA damage response and
chemosensitivity. The positive signaling feedback
between FLT3-ITD and DOCK2 upregulates the DNA
damage response (DDR) through RAC1 leading to a
decrease in chemosensitivity (CS) of acute myeloid
leukemia (AML) cells. The balance can be tilted in
favor of chemotherapy by downregulation of DOCK2
or inhibition of FLT3-ITD or DDR proteins which sen-
sitizes the AML cells.
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Pathophysiology and current therapies in chronic 
lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most fre-
quent leukemia in western countries. It is characterized
by the accumulation of mature B lymphocytes in the
peripheral blood, peripheral lymphoid organs and bone
marrow. CLL displays a heterogeneous clinical course,
ranging from protracted indolent disease with no require-
ment for treatment in some patients to rapid disease pro-
gression and subsequent treatment refractoriness in oth-
ers.1-3
CLL progression is a reflection of the complex interplay
between genomic drivers of disease and interactions with
the microenvironment.4 Whole genome/exome profiling
by next-generation sequencing has revealed that the clon-
al composition of CLL is constantly reshaped during dis-
ease progression. It has been proposed that CLL exhibits
a stochastic model of progression with the existence of a
‘trunk’ tumor population and numerous ‘branches’ that
can act as tumor progenitors. According to this model,
the subclonal topography of CLL arises over time as a
result of an initial driver mutation which leads to malig-
nant transformation and is observed in all tumor cells –
the trunk population. This is followed by secondary driv-
er mutations in distinct subclones which are selected by
intraclonal competition or treatment, and are likely to
contribute to disease progression. Finally, CLL relapse has
been attributed to the expansion of highly fit, often treat-
ment-selected subclones (branches) carrying mutations in
the DNA damage response (DDR) genes TP53 and ATM,
SF3B1 or NRAS.5,6 As a result, a significant proportion of
relapsed/refractory CLL can be attributed to the function-
al loss of the DDR.
For several decades, alkylating agents and purine
analogs were the principal therapies for CLL, augmented
by the addition of monoclonal antibodies. The last
decade has seen an expansion in the number of com-
pounds targeting specific aspects of the CLL phenotype,
from the interactions of tumor cells with the microenvi-
ronment and B-cell receptor signaling to anti-apoptotic
cellular pathways, heralding a new era of CLL therapy
based on targeted treatment approaches.7-10 In particular,
new inhibitors of signaling pathways that are critical to
CLL survival and proliferation, such as Bruton tyrosine
kinase (BTK), phosphoinositide-3 kinase (PI3K), and the
anti-apoptotic protein Bcl-2, have changed the manage-
ment of many CLL patients.
Despite the array of available therapeutic options, CLL
remains, at present, an incurable condition.11 Firstly, the
acquisition of DDR gene defects such as TP53 deletions
and/or mutations renders CLL patients refractory to con-
ventional chemoimmunotherapies. The clinical response
to the BTK inhibitor, ibrutinib, is encouraging for some
but not all refractory tumors.12 Secondly, clonal selection
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